Hepatokine fibrinogen-like protein 1 drives liver-kidney crosstalk to promote renal fibrosis

分享:

简介:

  • 作者: Wen-Hui Wu, Li-Zeng Zhu, Kang Liu, Lin Cao, Yuan-Ming Fan, Ping Zhou, Yue Zhang, Gaoxiang Ma, Jin-Feng Liu, Bao-Lin Liu, Lian-Wen Qi, Qun Liu
  • 杂志: Nature Communications
  • Doi: https://www.doi.org/10.1038/s41467-025-68188-0
  • 出版日期: 2026/1/9

论文中使用的产品/服务

询价

摘要

The concept of organ-organ communication in systemic diseases has gained significant traction. Despite accumulating evidence of liver-kidney crosstalk, the underlying regulatory mechanisms remain poorly understood. Here, we identify hepatokine fibrinogen-like protein 1 (FGL1) as a pivotal mediator driving liver-kidney communication in renal fibrosis. Integrative RNA sequencing and clinical analyses revealed FGL1 upregulation in the liver post-renal injury, with subsequent selective accumulation in fibrotic kidneys. Hepatocyte-specific knockout of FGL1 improved renal morphology, attenuated collagen deposition, and inhibited fibrosis markers in unilateral ureteral obstruction and adenine-induced mouse models. Conversely, FGL1 overexpression exacerbated renal fibrosis. Mechanistically, FGL1 binds to TGF-β receptor ALK5 and blocks its interaction with K48-linked polyubiquitin. Structural analyses identified critical residues in FGL1-ALK5 interaction. Hepatic FGL1 is transcriptionally regulated by STAT3, and activated by inflammatory cytokines (IL-6, IL-1β and TNF-α). Pharmacological inhibition by p-hydroxybenzaldehyde (screened out from 4080 compounds) or an anti-FGL1 monoclonal antibody significantly reduced renal fibrosis without hepatotoxicity. These findings establish FGL1 as a key mediator of pathogenic liver-kidney crosstalk and highlights therapeutic strategies to targeting organ-organ networks in renal fibrosis.

关于派真

作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IITINDBLA的各个阶段。

 

凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。

下载

用户登录

还没账号? 请注册
手机验证码登录
账号密码登录
手机号码*
验证码*
忘记密码?

首次使用手机号登录将自动为您注册

登录即代表阅读并接受《注册协议》 《用户协议》

新用户注册

已有账号?
手机注册
邮箱注册
手机号码*
验证码*
机构名称*
客户类型*

重置密码

手机找回密码
邮箱找回密码
手机号码*
验证码*
设置新密码*
确认新密码*